Physician profile
Didi E Omiyi
NPI 1467618561
$94,716.34
in general payments reported to CMS, 2019-2025
9 companies · $666 in 2025
The $666 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,748 · 2020: $14K · 2021: $38K · 2022: $25K · 2023: $12K · 2024: $46.58 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Travel and Lodging: $913 · Food and Beverage: $837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,000.00 |
| Travel and Lodging | $912.96 |
| Food and Beverage | $837.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $87,785.56 | 2019-2025 | Persona |
| Stryker Corporation | $5,302.94 | 2019-2025 | Mako |
| Ortho Development Corporation | $1,241.18 | 2022-2025 | |
| Smith+Nephew, INC. | $209.61 | 2019 | |
| Orthofix Medical, INC. | $62.31 | 2020-2025 | Physio-Stim |
| Pacira Pharmaceuticals Incorporated | $39.30 | 2023-2025 | Exparel, Zilretta, Iovera |
| Depuy Synthes Sales INC. | $28.81 | 2021 | |
| Pacira Therapeutics, INC. | $25.81 | 2019-2020 | |
| Kci USA, INC. | $20.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Didi Omiyi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.